CY1121981T1 - Μεθοδος για τον προσδιορισμο κινδυνου pml - Google Patents

Μεθοδος για τον προσδιορισμο κινδυνου pml

Info

Publication number
CY1121981T1
CY1121981T1 CY20191100584T CY191100584T CY1121981T1 CY 1121981 T1 CY1121981 T1 CY 1121981T1 CY 20191100584 T CY20191100584 T CY 20191100584T CY 191100584 T CY191100584 T CY 191100584T CY 1121981 T1 CY1121981 T1 CY 1121981T1
Authority
CY
Cyprus
Prior art keywords
determination
pml risk
pml
risk
patient
Prior art date
Application number
CY20191100584T
Other languages
English (en)
Inventor
Meena Subramanyam
Tatiana Plavina
Gary Lewis BLOOMGREN
Carmen Bozic
Sophia Lee
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47260338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121981(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of CY1121981T1 publication Critical patent/CY1121981T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Exhaust Gas After Treatment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

Η εφεύρεση αφορά μεθόδους προσδιορισμού του κινδύνου για έναν ασθενή να αναπτύξει Προοδευτική πολυεστιακή λευκοεγκεφαλοπάθεια (PML).
CY20191100584T 2011-05-31 2019-06-03 Μεθοδος για τον προσδιορισμο κινδυνου pml CY1121981T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161491810P 2011-05-31 2011-05-31
US201161508584P 2011-07-15 2011-07-15
US201161550257P 2011-10-21 2011-10-21
US201261636588P 2012-04-20 2012-04-20
PCT/US2012/040283 WO2012166971A2 (en) 2011-05-31 2012-05-31 Method of assessing risk of pml

Publications (1)

Publication Number Publication Date
CY1121981T1 true CY1121981T1 (el) 2020-10-14

Family

ID=47260338

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100584T CY1121981T1 (el) 2011-05-31 2019-06-03 Μεθοδος για τον προσδιορισμο κινδυνου pml

Country Status (20)

Country Link
US (3) US12105090B2 (el)
EP (3) EP3575792B1 (el)
JP (5) JP6243838B2 (el)
KR (3) KR102292563B1 (el)
CN (1) CN103635803A (el)
AU (1) AU2012262122B2 (el)
CA (1) CA2836490A1 (el)
CY (1) CY1121981T1 (el)
DK (2) DK3575792T3 (el)
ES (2) ES2939482T3 (el)
FI (1) FI3575792T3 (el)
HR (2) HRP20190860T1 (el)
HU (2) HUE043339T2 (el)
LT (2) LT3575792T (el)
PL (2) PL3575792T3 (el)
PT (2) PT2715352T (el)
RS (2) RS58967B1 (el)
SI (2) SI3575792T1 (el)
SM (2) SMT201900336T1 (el)
WO (1) WO2012166971A2 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2752137T3 (es) 2006-02-28 2020-04-03 Biogen Ma Inc Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab
WO2007103112A2 (en) 2006-03-03 2007-09-13 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
EP2485762B1 (en) 2009-10-11 2017-12-13 Biogen MA Inc. Anti-vla-4 related assays
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
RS56977B1 (sr) 2010-01-11 2018-05-31 Biogen Ma Inc Test za antitela protiv jc virusa
PL3575792T3 (pl) 2011-05-31 2023-03-27 Biogen Ma Inc. Metoda oceny ryzyka postępującej wieloogniskowej leukoencefalopatii (pml)
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHOD FOR ASSESSING A PML RISK
US20160223565A1 (en) * 2013-09-18 2016-08-04 The Johns Hopkins University Bk virus serology assessment of progressive multifocal leukoencephalopathy (pml) risk
US10955422B2 (en) 2014-02-27 2021-03-23 Biogen Ma, Inc. Method of assessing risk of PML
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
CA3080239A1 (en) 2017-10-26 2019-05-02 Biogen Ma Inc. Extended interval dosing of natalizumab
CA3198318A1 (en) 2020-11-14 2022-05-19 Yuan Zhao Biphasic subcutaneous dosing regimens for anti-vla-4 antibodies
JP2024513974A (ja) 2021-04-13 2024-03-27 バイオジェン・エムエイ・インコーポレイテッド 慢性活動性白質病変／放射線学的孤立性症候群を治療するための組成物及び方法

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
JP2868900B2 (ja) 1991-01-11 1999-03-10 クイデル コーポレイション ワンステップ側方流非吸収性アッセイ
US5213796A (en) 1991-05-06 1993-05-25 Dana Farber Cancer Institute Assay for polyomavirus in humans and uses thereof
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
WO1993015217A1 (en) 1992-02-04 1993-08-05 Quidel Corporation Simplified extraction method for bacterial antigens using dried reagents
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
WO1993018398A1 (en) 1992-03-10 1993-09-16 Quidel Corporation Red blood cell separation means for specific binding assays
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
PT1232392E (pt) 1999-10-12 2003-08-29 Connex Ges Optimierung Von For Processo melhorado para deteccao nas fezes de bacterias do genero helicobacter resistentes ao acido
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
JP2003517023A (ja) 1999-12-16 2003-05-20 バイオジェン インコーポレイテッド 中枢神経系の虚血性損傷または出血性損傷を、抗α４インテグリンアンタゴニストを用いて処置する方法
AU2001233034A1 (en) 2000-01-27 2001-08-07 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
EP1271152A4 (en) 2000-03-30 2005-04-27 Nippon Kayaku Kk METHOD FOR DETECTING CANCER BY MEASURING AUTOANTIC VIRUSES AGAINST MDM2 AND REAGENTS THEREFOR
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
DE60135147D1 (de) 2000-10-17 2008-09-11 Besst Test Aps Nen biologischen zelle in einer körperflüssigkeitsprobe
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
WO2003016902A1 (en) 2001-08-20 2003-02-27 Proteome Systems Intellectual Property Pty Ltd Diagnostic testing process and apparatus
US6605602B1 (en) 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
AU2002357779A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Identification of high affinity molecules by limited dilution screening
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
WO2004001539A2 (en) 2002-06-21 2003-12-31 Mckesson Information Solutions Llc Closed loop medication use system and method
WO2007008690A2 (en) * 2005-07-08 2007-01-18 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Methods for monitoring neuroinflammatory destruction of neurons and for treating diseases having an inflammatory component related to phospholipase a2
US20070275481A1 (en) 2003-11-24 2007-11-29 Biogen Idec Ma Inc. Methods For Detecting Half-Antibodies Using Chip Based Gel Electophoresis
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
TWI418346B (zh) 2004-07-08 2013-12-11 伊蘭製藥公司 包括聚合物部分之多價ｖｌａ-４拮抗劑
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP1833509A4 (en) 2004-12-03 2008-12-03 Biogen Idec Inc DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
EP3796003A1 (en) 2005-04-04 2021-03-24 Biogen MA Inc. Methods for evaluating an immune response to a therapeutic agent
ATE493405T1 (de) 2005-09-29 2011-01-15 Elan Pharm Inc Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
WO2007101165A1 (en) 2006-02-27 2007-09-07 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
ES2752137T3 (es) 2006-02-28 2020-04-03 Biogen Ma Inc Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab
US8410115B2 (en) 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
WO2007103112A2 (en) 2006-03-03 2007-09-13 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
EP2053961A4 (en) * 2006-08-09 2013-05-01 Biogen Idec Inc METHOD FOR DISPENSING A MEDICAMENT
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20080233150A1 (en) 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
EP1933140B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Antibody detection method involving an oligonucleotide enhanced collodial gold signal
TW200846363A (en) * 2007-03-22 2008-12-01 Urrma R & B Novel human anti-R7V antibodies and uses thereof
FR2919804B1 (fr) * 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
CN104195227B (zh) * 2008-11-07 2017-04-12 适应生物技术公司 通过序列分析监测状况的方法
NZ594973A (en) 2009-02-05 2012-05-25 Biogen Idec Inc Methods for the detection of JC polyomavirus and diagnosis of progressive multifocal leukoencephalopathy (PML)
CN102326080B (zh) 2009-02-20 2015-08-05 加利福尼亚大学董事会 A+生物标志物的试验
RS56977B1 (sr) * 2010-01-11 2018-05-31 Biogen Ma Inc Test za antitela protiv jc virusa
PL3575792T3 (pl) 2011-05-31 2023-03-27 Biogen Ma Inc. Metoda oceny ryzyka postępującej wieloogniskowej leukoencefalopatii (pml)
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHOD FOR ASSESSING A PML RISK

Also Published As

Publication number Publication date
ES2939482T3 (es) 2023-04-24
PT3575792T (pt) 2023-02-28
EP4187248A1 (en) 2023-05-31
SMT201900336T1 (it) 2019-07-11
WO2012166971A2 (en) 2012-12-06
SMT202300060T1 (it) 2023-03-17
JP2020101556A (ja) 2020-07-02
WO2012166971A3 (en) 2013-03-07
JP2014518377A (ja) 2014-07-28
JP6243838B2 (ja) 2017-12-06
KR20140038440A (ko) 2014-03-28
DK3575792T3 (da) 2023-02-27
AU2012262122A1 (en) 2013-11-14
EP2715352A2 (en) 2014-04-09
HRP20190860T1 (hr) 2019-06-28
JP7353338B2 (ja) 2023-09-29
JP2023169307A (ja) 2023-11-29
JP2022023126A (ja) 2022-02-07
JP6663396B2 (ja) 2020-03-11
KR20190122878A (ko) 2019-10-30
US12066442B2 (en) 2024-08-20
SI2715352T1 (sl) 2019-06-28
KR102292563B1 (ko) 2021-08-24
CA2836490A1 (en) 2012-12-06
PT2715352T (pt) 2019-06-12
HRP20230186T1 (hr) 2023-03-31
PL3575792T3 (pl) 2023-03-27
CN103635803A (zh) 2014-03-12
FI3575792T3 (fi) 2023-03-17
JP7128221B2 (ja) 2022-08-30
PL2715352T3 (pl) 2019-09-30
KR20210107138A (ko) 2021-08-31
KR102473834B1 (ko) 2022-12-02
WO2012166971A8 (en) 2013-01-17
HUE061244T2 (hu) 2023-06-28
US20250164486A1 (en) 2025-05-22
LT3575792T (lt) 2023-03-10
RS63989B1 (sr) 2023-03-31
US20190227064A1 (en) 2019-07-25
ES2729945T3 (es) 2019-11-07
LT2715352T (lt) 2019-06-10
EP3575792A1 (en) 2019-12-04
DK2715352T3 (da) 2019-05-20
SI3575792T1 (sl) 2023-04-28
KR102039751B1 (ko) 2019-11-01
RS58967B1 (sr) 2019-08-30
US12105090B2 (en) 2024-10-01
AU2012262122B2 (en) 2016-12-08
US20220011310A1 (en) 2022-01-13
EP3575792B1 (en) 2022-11-30
EP2715352A4 (en) 2015-10-21
HUE043339T2 (hu) 2019-08-28
JP2017191111A (ja) 2017-10-19
EP2715352B1 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
CY1121981T1 (el) Μεθοδος για τον προσδιορισμο κινδυνου pml
HK1216546A1 (zh) 评估pml风险的方法
IL265155A (en) A method for determining an increased risk of developing Alzheimer's disease
EA201590027A1 (ru) Способы детекции заболеваний или состояний
EA201490533A1 (ru) Способы и композиции для определения статуса в отношении курения
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
EP3757224A3 (en) Method of assessing risk of pml
EP2698381A4 (en) ANTIBODIES, KIT AND METHOD FOR DETERMINING AMYLOID PEPTIDES
UA110813C2 (uk) Лікування ліподистрофії
EA201590172A1 (ru) ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
FR2987920B1 (fr) Procede de determination d'une caracteristique geometrico-morphologique, de posture ou comportementale d'un porteur d'une paire de lunettes
UY4153Q (es) Batería
EP3480600C0 (en) METHODS FOR DETECTING KIDNEY DISEASE
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
MX2013014622A (es) Enfermedad tromboembolica.
UY33930A (es) Inhibidores novedosos de quinasas
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
UY34097A (es) Alineación de anticoagulante de cebado para extracción de sangre.
FR2956223B1 (fr) Lentille ophtalmique multifocale progressive
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
BR112015009042A8 (pt) Método para identificar uma população de célula renal heterogênea adequada para implantação e/ou desencadeamento de uma resposta regenerativa
BR112012029985A2 (pt) métodos de determinação de rotatividade beta-amiloide no sangue.
MA38171A1 (fr) Insuffisance rénale aigue
EP2911340A4 (en) METHOD AND SYSTEM FOR TROUBLESHOOTING ON AN INTERNET-THAT-GATEWAY
MX381530B (es) Método in vitro para el diagnóstico de la enfermedad de niemann-pick.